Allogeneic cellular immunotherapies hold a great promise for cancer treatment owing to their potential cost-effectiveness, scalability and on-demand availability. One of the main challenges to achieve clinical responses to the same level as CAR-T cells is the immune rejection of the therapeutic cells by the immune system of the patient.
In this review published April 24, the authors discuss gene editing and synthetic biology strategies to confer properties to allogeneic cell products that allows therapeutic cells to evade and delay the immune rejection from the host, thereby widening the therapeutic window.
Postdoc Karen E. Martin in the Malmberg group is the first author on this review that is part of a long standing and excellent collaboration with Michel Sadelain’s group at Memorial Sloan Kettering Cancer Center, New York, US.
- Martin, K.E., Hammer, Q., Perica, K. et al. Engineering immune-evasive allogeneic cellular immunotherapies. Nat Rev Immunol (2024). https://doi.org/10.1038/s41577-024-01022-8